Journal of Surgical Oncology

The Journal of Surgical Oncology is a peer-reviewed journal devoted to the operative treatment of cancer, published by Wiley in Hoboken, New Jersey, for the World Federation of Surgical Oncology Societies.《外科肿瘤学杂志》是一本聚焦肿瘤外科治疗的同行评议期刊，由 Wiley 在美国新泽西州霍博肯出版，并担任世界外科肿瘤学会联合会的代表刊物。

It began in 1969 and reports a 2025 Journal Impact Factor of 1.9, with clinical series, translational laboratory work and invited reviews appearing across sixteen issues each year.该刊创刊于 1969 年，2025 年期刊影响因子为 1.9，每年出版十六期，内容涵盖临床系列研究、转化实验室工作与约请综述。

Scope

• The scope covers peer-reviewed original papers in surgical oncology and broadly related surgical sciences, including experimental and laboratory reports.收稿范围覆盖外科肿瘤学及广泛相关外科科学的同行评议原创论文，含实验与实验室研究报告。
• Clinical work on the resection of solid tumours forms the core, from patient selection and staging through operative strategy and pathological correlation.实体瘤切除的临床研究构成核心，内容从患者筛选与分期延伸到手术策略和病理对照。
• Breast disease is a long-standing section, with sentinel node practice, breast-conserving surgery and oncoplastic reconstruction all represented.乳腺疾病是长期设置的板块，前哨淋巴结实践、保乳手术与肿瘤整形重建均有覆盖。
• Colorectal contributions range from rectal excision and neoadjuvant sequencing to laparoscopic and robotic technique.结直肠方向的来稿从直肠切除与新辅助治疗序贯安排，一直延伸到腹腔镜与机器人技术。
• Advanced gastrointestinal and peritoneal surface malignancy is a defined area, including cytoreductive surgery with heated intraperitoneal chemotherapy.晚期胃肠与腹膜表面恶性肿瘤是明确设置的领域，涵盖肿瘤细胞减灭术联合腹腔热灌注化疗。
• Cutaneous oncology, melanoma sentinel node biopsy and regional nodal management appear regularly in the submitted and invited content.皮肤肿瘤、黑色素瘤前哨淋巴结活检与区域淋巴结处理，常在投稿与约稿内容中出现。
• Biomarker discovery and validation is treated as a standing theme, linking tissue and circulating markers to surgical decision making.生物标志物的发现与验证是常设主题，把组织与循环标志物同手术决策连接起来。
• Translational laboratory studies of tumour biology, drug response and wound healing are accepted alongside patient-based research.肿瘤生物学、药物反应与创面愈合的转化实验室研究，与基于患者的研究一并接收。
• Perioperative care, complication reporting and quality improvement work sit within the remit, as do audits of surgical outcomes at institutional and national scale.围手术期管理、并发症报告与质量改进工作同样在范围内，机构层面与国家层面的手术结局审计亦在其中。
• Health services questions such as access, centralisation of cancer surgery and volume-outcome relations are published when the analysis is sound.就诊可及性、肿瘤手术集中化与手术量与结局关系等卫生服务问题，在分析可靠时会予以发表。
• Multidisciplinary sequencing with medical and radiation oncology is examined in papers that follow patients across combined treatment pathways.与肿瘤内科、放射肿瘤科的多学科序贯在论文中受到考察，这类研究沿联合治疗路径追踪患者。
• Education and training in surgical oncology appear in the record, including learning theory applied to technical skills and curriculum design for accreditation.外科肿瘤学的教育与培训也见于刊物记录，包括把学习理论用于技术技能训练，以及面向认证的课程设计。
• Review articles are commissioned or accepted when they synthesise a field in depth rather than summarise a single service.综述文章在能深入综合某一领域而非概述单一科室工作时，会获约稿或接收。
• Letters to the Editor and invited editorials provide short-form comment, and thematic Seminars issues collect invited reviews around one clinical problem.致编辑的信与约请社论提供短篇评论，主题式研讨专号则围绕单一临床问题汇集约稿综述。
• Authors from outside North America are actively sought, and the editors describe participation from leading surgeons around the world as central to the title.北美以外的作者受到主动争取，编辑部把世界各地顶尖外科医生的参与视为刊物的要务。

History

• Volume 1 appeared in 1969 from New York, and the National Library of Medicine has indexed the title in Index Medicus and MEDLINE from that first issue onward.第 1 卷于 1969 年在纽约问世，美国国家医学图书馆自创刊号起就把该刊收入《医学索引》与 MEDLINE。
• NLM records the early imprint as Plenum in New York, while the current imprint is Wiley-Liss of Hoboken, New Jersey, in force since 2005.美国国家医学图书馆记录的早期出版者为纽约的 Plenum，现行出版者则为新泽西州霍博肯的 Wiley-Liss，自 2005 年起沿用。
• The Wiley-Liss name on the masthead traces back to the 1989 purchase of the New York medical publisher Alan R. Liss by John Wiley and Sons.刊名页上的 Wiley-Liss 名称，可追溯到 1989 年约翰威立国际出版公司对纽约医学出版商 Alan R. Liss 的收购。
• Sixteen issues now appear each year in two volumes of eight, a cadence NLM dates from 2005, when extra issues were added in four months of the year.如今每年出版十六期，分成两卷、每卷八期，这一节奏被美国国家医学图书馆记为 2005 年确立，当年在一年中的四个月各增出一期。
• Crossref records for 2025 list volumes 131 and 132, each running from issue 1 to issue 8, which matches the two-volume annual pattern.Crossref 的 2025 年记录列出第 131 卷与第 132 卷，两卷均从第 1 期排到第 8 期，与每年两卷的格局吻合。
• The journal became the representative publication of the World Federation of Surgical Oncology Societies, a role the publisher states on the title page.该刊成为世界外科肿瘤学会联合会的代表刊物，出版方在刊名页上标明了这一身份。
• Thematic Seminars issues grew into a fixture, each one assembled by guest editors drawn from the editorial board and filled with invited reviews on a single problem.主题研讨专号逐渐成为固定栏目，每期由编委会中抽出的客座编辑组稿，围绕单一问题刊登约稿综述。
• Print carrying the ISSN 0022-4790 was joined by an electronic edition under ISSN 1096-9098, and the full text now sits on Wiley Online Library with early view posting.承载 ISSN 0022-4790 的印刷版之外增加了 ISSN 1096-9098 的电子版，全文现于 Wiley Online Library 发布，并支持提前在线刊登。
• Access is hybrid, and JCR data for 2025 put the share of gold open access articles at roughly 32 percent, paid through the publisher's OnlineOpen route.该刊为混合获取模式，2025 年的 JCR 数据把金色开放获取文章的比例记为约 32%，相关费用经出版方的 OnlineOpen 渠道支付。
• Impact factors drifted downward after 2022, from 2.885 that year to 2.0 in 2023 and 1.9 in both 2024 and 2025.影响因子在 2022 年之后逐步回落，当年为 2.885，2023 年降至 2.0，2024 年与 2025 年均为 1.9。
• Citation volume remains substantial, with 11,539 citations counted in 2025 against 192 articles and a cited half-life of 8.3 years.被引规模依然可观，2025 年统计到 11539 次引用，对应 192 篇论文，被引半衰期为 8.3 年。
• Category placement is split, with the title ranked 259 of 333 in ONCOLOGY for a Q4 position and 145 of 321 in SURGERY for Q2.类目位置出现分化，该刊在 ONCOLOGY 类目以 259/333 列入 Q4，在 SURGERY 类目以 145/321 列入 Q2。
• NLM's catalogue entry also lists two ISSNs of undetermined type, 8756-0437 and 1046-7416, beside the two numbers now in use.美国国家医学图书馆的目录记录在两枚现行编号之外，另列 8756-0437 与 1046-7416 两枚类型未定的 ISSN。

Editors

• Stephen F. Sener of the University of Southern California holds the editor-in-chief position and sets the clinical direction of the title.主编（Stephen F. Sener）任职于南加州大学，负责把握刊物的临床方向。
• David Bentrem of Northwestern University works as deputy editor, taking manuscripts that need a second senior opinion.副主编（David Bentrem）来自西北大学，负责处理需要第二位资深意见的稿件。
• Two editors emeriti, Walley J. Temple and Gerald P. Murphy, remain listed on the masthead in an honorary capacity.两位荣休主编（Walley J. Temple）与（Gerald P. Murphy）仍以荣誉身份列在编委页上。
• The board is organised by disease site rather than by method, with named sections for breast, colorectal, cutaneous and advanced gastrointestinal disease.编委会按疾病部位而非方法划分，设有乳腺、结直肠、皮肤与晚期胃肠疾病等具名板块。
• Breast is the largest section, staffed by V. Suzanne Klimberg, Isabel T. Rubio and Benjamin O. Anderson among others.乳腺板块规模最大，编委包括（V. Suzanne Klimberg）、（Isabel T. Rubio）与（Benjamin O. Anderson）。
• Colorectal is covered by Anthony Senagore and Scott R. Steele, while Mary S. Brady leads the cutaneous group.结直肠方向由（Anthony Senagore）与（Scott R. Steele）负责，皮肤方向由（Mary S. Brady）领衔。
• Cross-cutting expertise sits in separate sections for biomarkers, led by Janardan D. Khandekar and William E. Carson III, and for biostatistics under Elizabeth Hahn.跨领域专长分设生物标志物与生物统计两个板块，前者由（Janardan D. Khandekar）与（William E. Carson III）主持，后者由（Elizabeth Hahn）负责。
• Membership reaches beyond the United States, with advisers drawn from surgical centres in Europe and Latin America, and further representatives from Asia and the Middle East.编委并不限于美国，成员来自欧洲与拉丁美洲的外科中心，亚洲和中东亦有代表。
• Manuscripts enter through the publisher's online submission system, where research articles, reviews and correspondence follow separate handling tracks.稿件经出版方的在线投稿系统进入，研究论文、综述与通信各自走不同的处理流程。
• Submitted work is refereed externally, and the editorial office returns decisions with reviewer reports to corresponding authors.来稿送外部评审，编辑部把决定连同审稿人报告一并回复给通讯作者。
• Guest editors from the board assemble the Seminars issues, inviting reviews that map a topic from diagnosis through operative management.编委会中的客座编辑负责组织研讨专号，约请综述把某一课题从诊断一直梳理到手术处理。
• Letters give readers a channel to contest published findings, and invited editorials frame selected papers for a general surgical readership.致编辑的信为读者提供质疑已发表结果的渠道，约请社论则为普通外科读者评述选定论文。